NEW YORK (GenomeWeb News) – Quanterix said today it has entered an agreement with Novartis to evaluate its Single Molecule Array, or SiMoA, platform for diagnostic use.
The platform will be evaluated at Quanterix, based in Cambridge, Mass., and will focus on an undisclosed neuron-specific protein target. Financial and other terms of the deal were also undisclosed.
The SiMoA platform is used for the development and commercialization of blood tests that measure protein levels in blood.
David Okrongly, president and CEO of Quanterix, in a statement called the deal "an important milestone" for the company. "Through this collaborative project, we hope to leverage the 1,000-fold sensitivity improvement of SiMoA technology to develop a novel class of valuable diagnostic tests that will provide greater insight into disease and improve patient outcomes," he said.